09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain) Download PDF Post navigationPreviousPrevious post:Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per shareNextNext post:AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042Related PostsAB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026Annual financial results as of 31 December, 202513 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026
